ALGS · Aligos Therapeutics Inc.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Market Cap
7.623M
52 Wk Range
$1.18 - $13.69
Previous Close
$1.25
Open
$1.26
Volume
106,836
Day Range
$1.18 - $1.34
Enterprise Value
-11.38M
Cash
31.09M
Avg Qtr Burn
N/A
Insider Ownership
10.64%
Institutional Own.
46.58%
Qtr Updated
Sep 30th 2026
